Navigation Links
Transcept Pharmaceuticals, Inc. to Present at the 20th Annual Piper Jaffray Health Care Conference
Date:11/24/2008

PT. RICHMOND, Calif., Nov. 24 /PRNewswire/ -- Transcept Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, announced today that Glenn A. Oclassen, President & Chief Executive Officer, is scheduled to present at the 20th Annual Piper Jaffray Health Care Conference in New York City on Tuesday, December 2, 2008 at 8:00 AM Eastern Time.

An audio webcast of the presentation will be available at http://www.piperjaffray.com/conferences. The replay of the presentation will be available for 30 days.

About Transcept Pharmaceuticals

Transcept Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the fields of psychiatry and sleep medicine. The lead Transcept product candidate, Intermezzo(R), is a sublingual low dose formulation of zolpidem that has been developed for use as-needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep. Phase 3 clinical trials have been completed for Intermezzo(R) and, on September 30, 2008, Transcept submitted a New Drug Application to the U.S. Food and Drug Administration.

For further information, please visit the company's website at: http://www.transcept.com.

Safe Harbor

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Transcept disclaims any intent or obligation to update these forward-looking statements, and claim the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the expected benefits of Transcept product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, Transcept product candidates may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA approval; physician or patient reluctance to use Intermezzo(R), if approved; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in, clinical development, obtaining regulatory approval, market acceptance and commercialization of Transcept product candidates.

     Contacts:

     Transcept Pharmaceuticals, Inc.        The Ruth Group
     Michael Gill                           Investors / Media
     Director of Communications             Stephanie Carrington / Jason Rando
     (510) 215-3575                         (646) 536-7017 / 7025
     mgill@transcept.com                    scarrington@theruthgroup.com
                                            jrando@theruthgroup.com

'/>"/>
SOURCE Transcept Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Transcept Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
2. Transcept Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
3. Transcept Pharmaceuticals to Present at Cowen and Companys 27th Annual Health Care Conference in Boston
4. Transcept Pharmaceuticals to Present at the Susquehanna Financial Groups SIGnificant Investment Options in Healthcare Conference
5. Transcept Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
6. Transcept Pharmaceuticals to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
7. Transcept Pharmaceuticals to Present at RBC Capital Markets 2007 Healthcare Conference
8. Transcept Pharmaceuticals to Present at 19th Annual Piper Jaffray Health Care Conference
9. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
10. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
11. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... Dallas, TX (PRWEB) , ... ... ... HCC Risk Adjustment solution leverages advanced data analytics to accurately understand each ... ensure proper reimbursement for a given population. This new solution helps transform ...
(Date:2/22/2017)... ... February 22, 2017 , ... Sideline Products participated in the World ... TV host Tom Seay and his production crew. Tom Seay’s program “Best of ... the world. Saddle Sidekicks will be featured on April 6, 2017. After the ...
(Date:2/22/2017)... ... February 22, 2017 , ... ANGLESTRONG , the new recovery management app ... the App Store and Google Play . Florida-based Sober Network, Inc., ... recovery industry, partnered with Angle to build ANGLESTRONG. The new recovery management app is ...
(Date:2/22/2017)... ... ... A product of digesting a micronutrient found in soy may hold the key ... while others do not, a University of Pittsburgh Graduate School of Public Health-led study ... some types of “good” gut bacteria when they metabolize isoflavones (micronutrients found in dietary ...
(Date:2/22/2017)... ... 22, 2017 , ... Super-Sod will attend the Athens Home Show with a ... A shift from Super-Sod’s simple Athens Home Show booth of 2016, this year’s exhibit ... plant manager Chris Roquemore constructed furniture from recycled pallet wood at the Super-Sod farm ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... and PUNE, India , February 22, 2017 ... Market Research, titled, "Automated Radio Synthesis Modules Market: Global Opportunity ... radiosynthesis modules market was worth $20 million in 2015 and ... CAGR of 6.6% from 2016 to 2022. North ... of both market revenues and unit volumes, whereas ...
(Date:2/22/2017)... , Feb 22, 2017 Research and ... Drugs Market by Drug Molecule (Biologic, Small Molecule Drugs), By ... Inhibitors, Interleukin Blockers) Outlook 2022" report to their offering. ... The ... growth during 2016-2022 This report provides a detailed ...
(Date:2/22/2017)... , Feb. 22, 2017 The Senior Care ... U.S. Senate and House of Representatives that will curtail ... Managers (PBMs) -- from extracting retroactive direct and indirect ... care (LTC) pharmacies and the Medicare program. ... (R-WV) and Jon Tester (D-MT), and ...
Breaking Medicine Technology: